ACTOS (pioglitazone HCl) directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces. Glimepiride acts primarily by increasing the amount of insulin produced by the pancreas. These medications work in combination to help patients with type 2 diabetes manage their blood glucose levels. The company is seeking approval to bring the medication to market in the United States.
According to the American Diabetes Association, diabetes affects an estimated 18.2 million Americans. Type 2 diabetes is the most common form, and may account for about 90 to 95 percent of all diagnosed cases of diabetes.
ACTOS, an insulin sensitizer belonging to the thiazolidinedione (TZD) class of oral antidiabetic medications, directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS is taken once daily as an adjunct to diet and exercise, and is approved for type 2 diabetes for use as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas or metformin.
ACTOS is not for everyone. ACTOS can cause fluid retention that may lead to or worsen heart failure, so tell your doctor if you have a history of these conditions. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath while taking ACTOS. If you have moderate to severe heart failur
Contact: Amy Losak